H7N9 Anhui 2013/AA ca
/ National Institute of Allergy and Infectious Diseases
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 11, 2019
A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
(clinicaltrials.gov)
- P1; N=62; Completed; Sponsor: National Institute of Allergy and Infectious Diseases (NIAID); Active, not recruiting ➔ Completed
Clinical • Trial completion
1 to 1
Of
1
Go to page
1